In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.
Our Guests:
Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, Canada
Dr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, Canada
Note: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.html
This podcast episode was sponsored by Sanofi-Aventis Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.
Our Guests:
Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, Canada
Dr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, Canada
Note: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.html
This podcast episode was sponsored by Sanofi-Aventis Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com